[Trends in the treatment of cystic fibrosis].
Rossi
G
G
D002087:Butyrates / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D015316:Genetic Therapy; D019833:Genistein / Q000627:therapeutic use; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D020105:Milrinone / Q000627:therapeutic use; D009154:Mutation; D010654:Phenylbutyrates / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011794:Quercetin / Q000627:therapeutic use
D002087:Butyrates; C505032:CFTR protein, human; D006146:Guanidines; D007166:Immunosuppressive Agents; D010654:Phenylbutyrates; D010726:Phosphodiesterase Inhibitors; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D011794:Quercetin; D019833:Genistein; D020105:Milrinone; C037258:gusperimus
Prospettive nel trattamento della fibrosi cistica.